FDA Proposes Permanent Rare Pediatric Disease Priority Review Vouchers in 2027 Budget

The U.S. Food and Drug Administration (FDA) is seeking a fundamental shift in how it incentivizes the development of treatments for rare pediatric conditions. In its proposed budget for 2027, the agency is calling for the permanent authorization of the rare pediatric disease priority review voucher (PRV) program, moving away from the current cycle of temporary reauthorizations.

This proposal is part of a broader strategy to transition the FDA from a “reactionary system to a proactive system,” according to Commissioner Marty Makary. By providing more predictability for drug sponsors, the agency aims to ensure that patients with rare pediatric diseases maintain access to safe and effective therapies.

The 2027 FDA Budget Breakdown

The Trump administration has allotted $7.23 billion for the FDA in 2027. This represents an increase of approximately $232 million, or 3.2%, over the 2026 budget. This funding boost stands in contrast to the broader Department of Health and Human Services (HHS), which is projected to see its overall funds slashed by 12% to $111.1 billion for fiscal year 2027.

The FDA plans to use this “war chest” to implement several regulatory reforms designed to expedite drug development, strengthen national security, and promote what Commissioner Makary describes as “radical transparency.” Beyond the PRV program, the agency intends to ease the burdens associated with launching Phase 1 clinical trials within the United States.

Understanding the Rare Pediatric Disease PRV Program

The rare pediatric disease PRV program is designed to encourage pharmaceutical companies to invest in treatments for rare childhood diseases, which often lack the commercial appeal of mass-market drugs.

How the Voucher Works

Under the program, a sponsor that receives FDA approval for a drug or biological product targeting a rare pediatric disease may qualify for a priority review voucher. This voucher can be used in one of two ways:

• Direct Use: The sponsor redeems the voucher to receive a priority review for a different product. This reduces the FDA’s review time for that application from the standard 10 months to approximately six months.
• Transfer: Because vouchers are transferable, the original sponsor can sell them to another company. These vouchers are highly valuable, often selling for over $100 million.

The Path to Designation

To qualify for a PRV, sponsors typically request a “rare pediatric disease designation” before submitting their marketing application. This designation confirms the product meets the specific criteria required to potentially earn a voucher upon approval.

From Temporary Reauthorization to Permanence

Historically, the PRV program has required periodic reauthorization by Congress. Most recently, the Consolidated Appropriations Act, 2026 (which included the Mikaela Naylon Give Kids a Chance Act) reauthorized the program through September 30, 2029. Under current law, the FDA cannot award any PRVs after that date.

The 2027 budget proposal seeks to eliminate this “sunset” provision entirely. By making the program permanent, the FDA argues it will create “more predictability for sponsors,” encouraging long-term investment in rare disease research without the uncertainty of looming expiration dates.

Key Takeaways: FDA 2027 Proposal & PRV Program

• Budget Increase: The FDA’s 2027 budget is proposed at $7.23 billion, a $232 million increase.
• Permanent Vouchers: The agency wants to make the Rare Pediatric Disease PRV program permanent to stabilize incentives for sponsors.
• Review Acceleration: A PRV reduces the FDA review timeline for a subsequent drug from 10 months to roughly 6 months.
• Current Deadline: Without the new proposal, the current PRV program is set to sunset on September 30, 2029.
• Broader Reforms: The budget also targets easier entry for Phase 1 trials and increased regulatory transparency.

Looking Ahead

If the proposed budget and regulatory changes pass, the FDA will be better positioned to accelerate the pipeline for rare disease treatments. By removing the expiration date on the PRV program and lowering the barriers to early-stage clinical trials, the agency is betting that increased predictability will lead to more breakthroughs for the pediatric population.